Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mesenchymal Stromal Cells in Knee Osteoarthritis: A Review of Nomenclature, Criteria, and Therapeutic Mechanisms

Lim DH., Lee CC., Park KB.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Immune Modulation, published in Ther Clin Risk Manag (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Ther Clin Risk Manag (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42125733
PMCID
PMC13159940
DOI
10.2147/tcrm.s594869

Abstract (original English)

Cell-based therapies, particularly utilizing mesenchymal cells, have garnered significant global attention for treating knee osteoarthritis (OA). However, interpreting clinical outcomes remains challenging due to substantial heterogeneity in study designs, cell sources, and preparation methods. This narrative review aims to clarify the evolving nomenclature, outline defining criteria, and elucidate the fundamental mechanisms of these therapies. We highlight the critical scientific transition from "mesenchymal stem cells" to "mesenchymal stromal cells", an adjustment strongly supported by recent clinical approvals emphasizing immune recalibration over direct tissue regeneration. Currently, robust evidence indicates that mesenchymal stromal cells exert their therapeutic effects primarily through paracrine signaling and immunomodulation, predominantly orchestrated by exosomes, rather than through lineage-driven direct structural repair. Furthermore, we address the practical implications of cell processing-differentiating between minimal manipulation (e.g. cell concentrates) and in vitro expansion-and the stringent regulatory frameworks governing them. Ultimately, standardizing the mechanism-accurate "stromal" terminology and optimizing cell preparation protocols are essential steps for advancing the efficacy and reliability of regenerative treatments in knee OA.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research